Skip to main content
Premium Trial:

Request an Annual Quote

NCI to Issue Two Proteomics-Based RFPs This Fall

NEW YORK, Oct. 4 (GenomeWeb News) - The National Cancer Institute plans to issue a pair of RFPs this fall as part of its Clinical Proteomic Technologies Initiative.

 

The CPTI is an "integrated approach to develop and enhance proteomic technology capabilities to support the reliable discovery and measurement of cancer-associated proteins from readily accessible biological fluids," NCI said on its web site.

 

The first RFP will aim to create multiple 5-year awards to establish the Clinical Proteomic Technology Assessment Consortia through NIH U24 cooperative agreement funding mechanisms. The goal of the consortia will be "to optimize and standardize proteomic technology platforms, with an emphasis on mass spectrometry (MS)-based and affinity capture-based approaches," NCI said on its web site.

 

As part of the research, multidisciplinary teams will be required to address technology engineering, statistical design, and quantitative pathological assessments as applied to furthering our understanding of basic and clinical mechanisms of cancer, NCI said. A "key component" of the consortia will be to develop inter-laboratory protocols and analysis of biological samples from both mouse models and clinical specimens.

 

The CPTAC programs will support two overarching aims: to "develop and refine MS-based and affinity capture-based proteomic platforms to improve key factors such as experimental reproducibility, specificity, and mass accuracy, dynamic range, peptide/protein identification, individual peptide/protein quantification, sample throughput, and per sample/unit cost;" and "to develop a systematic assessment of the procedures and methodologies to minimize variability in MS and affinity capture-based measurements and data analyses," NCI said.

 

"Through standardizations and improvements, the CPTACs should aim to collectively identify and validate at least 1000 reproducible features of interest in cancer biospecimens by the end of the 5-year program and, at the same time, identify technologically superior platforms for MS-based and affinity capture-based proteomic analyses," NCI said.

 

These consortia will also "serve as critical sources of protocol development, education, and training to support standardized proteomic research platforms across the cancer research enterprise," NCI added.

 

Click here for more information about this RFP.


The second RFP will aim to "support investigator-initiated projects in Advanced Proteomic Platforms, Analytical Methods, and Computational Sciences to overcome current barriers in protein/peptide feature detection, identification, and quantification and develop mathematical, computational, and predictive approaches for the analysis and facile exchange of large-scale proteomic data," according to NCI.

The program is intended to "improve the development of technological and computational platforms that advance the performance of proteomic detection and identification in complex biological mixtures from mouse models and clinical specimens," NCI said.

Applicants "should demonstrate strong capabilities in statistical analysis and quality assurance of data. The R01 grant mechanism will be used to support bioinformatics and computational science programs, whereas the R21 and R33 mechanisms will be used to support the proteomic technology platforms. The goals of these projects include (but are not limited to) increased instrumental resolution capabilities, development of novel or advanced peptide/protein discovery technologies, integration of data and results from different analysis platforms, validation of proteomic methods and technologies, and improvements in data mining algorithms and data exchange formats."

The CPTI will "support the development of standards, resources, and clinical proteomic platforms for cancer research by harnessing efforts to establish standard references, quality control measures, and informatics platforms capable of aggregating and comparing data," NCI said.

 

Click here for this RFP.


These funding opportunities will be open to US-based academic, nonprofit, and for-profit institutions. NCI added that foreign institutions may be invited by eligible applicants to participate as subcontractors.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.